News | TCTAP 2021 Virtual

The Future of PCI: Indication, Technology, Outlook

Percutaneous coronary intervention (PCI) has gained incredible traction over the years - and leading cardiologists during a special keynote lecture at TCTAP 2021 Virtual on April 21 expounded in detail the direction of its promising future.

News | TCTAP 2021 Virtual

Atherosclerotic Plaque Progression and Imaging

The 11th winner of TCTAP award “Master of the Masters”

News | TCTAP 2021 Virtual

How Should Antithrombotic Strategies for CHIP and HBR Patients be tailored

Philip M. Urban, MD (Hopital de la Tour, Switzerland) addressed the prevalence of high bleeding risk (HBR) in patients of percutaneous coronary intervention (PCI) registries across multiple geographical regions at a session held during TCTAP 2021 Virtual.

News | TCTAP 2021 Virtual

iFR vs. FFR in Severe AS Patients: Which Is Better, and Is It Valid?

April 21th TCTAP Workshop Session of TCTAP 2021 Virtual

News | TCTAP 2021 Virtual

Percutaneous Treatment Considerations for Functional Mitral Regurgitation

Samir R. Kapadia, MD (Cleveland Clinic, Ohio, USA) discussed functional mitral regurgitation (MR) treatment considerations while sharing his experience with MitraClip Implant during a session at TCTAP 2021 Virtual that ran from April 21 to 24.

News | TCTAP 2021 Virtual

Chaos in Procedural MI (PMI) Definitions in PCI vs CABG Trials: How to Reconcile?

Patrick W. Serruys (NUI Galway, Ireland), examined the unresolved chaos regarding procedural MI (PMI) definition in PCI vs CABG trials during a session at TCTAP 2021 Virtual, suggesting possible upheaval of PMI definitions altogether.

News | TCTAP & AP VALVES 2020 Virtual

Choice of Stent Platforms in HBR Patients - Insights from the ONYX-ONE Trial

August 8th, Highlight Session of TCTAP & AP VALVES 2020 VIRTUAL